Objective： To systematically evaluate the efficacy and safety of Yiyiren Decoction combined with western medicine and western medicine alone in the treatment of rheumatoid arthritis. Methods： Databases of CNKI, VIP...Objective： To systematically evaluate the efficacy and safety of Yiyiren Decoction combined with western medicine and western medicine alone in the treatment of rheumatoid arthritis. Methods： Databases of CNKI, VIP, Wanfang Data, PubMed, Medline, Cochrane Library, and Embase were retrieved by computers. The references of the included studies, relevant dissertations, and conference proceedings were manually retrieved. The search intervals were from the database inception until July 2017. The retrieval and screening of studies were carried out respectively by 2 researchers, and the quality and data were evaluated and extracted according to Jadad quality scale. Meta-analysis was performed with RevMan5.3 software. Results： （1） A total of 7 randomized controlled trials and 485 patients were enrolled, among which 262 cases were in experimental group and 223 cases were in control group. The point of 2 studies was 3, other studies were 1-2. The studies included indicated that the group baselines were comparable. （2）The total effective rate of Yiyiren Decoction with western medicine group was higher than that of western medicine group （RR = 0.85, 95%CI [0.78, 0.92]. Improved Conditions of tender joint count （MD = -2.79, 95%CI [-3.47, -2.12]）; erythrocyte sedimentation rate （MD = -9.5, 95%CI [15.67, -3.33]）; and C-reactive protein （MD = -3.36, 95%CI [-5.45, -1.27]） were superior to control group. There was no significant difference on the side effects of drugs and the rheumatoid factor between the two groups. Conclusion： Yiyiren Decoction with western medicine had advantages in alleviating clinical symptoms and laboratory index of rheumatoid arthritis patients. While, the quality of included studies was low and possible publication bias was present, further multi-center double-blind randomized control trials with larger sample are needed.展开更多
BACKGROUND Herba Patriniae and Coix seed(HC)constitute a widely utilized drug combination in the clinical management of colorectal cancer(CRC)that is known for its diuretic,anti-inflammatory,and swelling-reducing prop...BACKGROUND Herba Patriniae and Coix seed(HC)constitute a widely utilized drug combination in the clinical management of colorectal cancer(CRC)that is known for its diuretic,anti-inflammatory,and swelling-reducing properties.Although its efficacy has been demonstrated in a clinical setting,the active compounds and their mechanisms of action in CRC treatment remain to be fully elucidated.AIM To identify the active,CRC-targeting components of HC and to elucidate the mechanisms of action involved.METHODS Active HC components were identified and screened using databases.Targets for each component were predicted.CRC-related targets were obtained from human gene databases.Interaction targets between HC and CRC were identified.A“drug-ingredient-target”network was created to identify the core components and targets involved.Gene Ontology(GO)and Kyoto Encyclopedia of Genes and Genomes(KEGG)analyses were conducted to elucidate the key pathways involved.Molecular docking between core targets and key components was executed.In vitro experiments validated core monomers.RESULTS Nineteen active components of HC were identified,with acacetin as the primary active compound.The predictive analysis identified 454 targets of the active compounds in HC.Intersection mapping with 2685 CRC-related targets yielded 171 intervention targets,including 30 core targets.GO and KEGG analyses indicated that HC may influence the phosphoinositide 3-kinase(PI3K)/Akt signaling pathway.Molecular docking showed that acacetin exhibited an optimal interaction with AKT1,identifying PI3K,AKT,and P53 as key genes likely targeted by HC during CRC treatment.Acacetin inhibited HT-29 cell proliferation and migration,as well as promoted apoptosis,in vitro.Western blotting analysis revealed increased p53 and cleaved caspase-3 expression and decreased levels of p-PI3K,p-Akt,and survivin,which likely contributed to CRC apoptosis.CONCLUSION Acacetin,the principal active compound in the HC pair,inhibited the proliferation and migration of HT-29 cells and promoted apoptosis through the PI3K/Akt/p53 signaling pathway.展开更多
文摘Objective： To systematically evaluate the efficacy and safety of Yiyiren Decoction combined with western medicine and western medicine alone in the treatment of rheumatoid arthritis. Methods： Databases of CNKI, VIP, Wanfang Data, PubMed, Medline, Cochrane Library, and Embase were retrieved by computers. The references of the included studies, relevant dissertations, and conference proceedings were manually retrieved. The search intervals were from the database inception until July 2017. The retrieval and screening of studies were carried out respectively by 2 researchers, and the quality and data were evaluated and extracted according to Jadad quality scale. Meta-analysis was performed with RevMan5.3 software. Results： （1） A total of 7 randomized controlled trials and 485 patients were enrolled, among which 262 cases were in experimental group and 223 cases were in control group. The point of 2 studies was 3, other studies were 1-2. The studies included indicated that the group baselines were comparable. （2）The total effective rate of Yiyiren Decoction with western medicine group was higher than that of western medicine group （RR = 0.85, 95%CI [0.78, 0.92]. Improved Conditions of tender joint count （MD = -2.79, 95%CI [-3.47, -2.12]）; erythrocyte sedimentation rate （MD = -9.5, 95%CI [15.67, -3.33]）; and C-reactive protein （MD = -3.36, 95%CI [-5.45, -1.27]） were superior to control group. There was no significant difference on the side effects of drugs and the rheumatoid factor between the two groups. Conclusion： Yiyiren Decoction with western medicine had advantages in alleviating clinical symptoms and laboratory index of rheumatoid arthritis patients. While, the quality of included studies was low and possible publication bias was present, further multi-center double-blind randomized control trials with larger sample are needed.
基金Supported by the National Natural Science Foundation of China,No.82174464China Academy of Traditional Chinese Medicine Science and Technology Innovation Project,No.CI2021A01806Central High Level Traditional Chinese Medicine Hospital Clinical Research and Achievement Transformation Ability Enhancement Project,No.HLCMHPP2023085.
文摘BACKGROUND Herba Patriniae and Coix seed(HC)constitute a widely utilized drug combination in the clinical management of colorectal cancer(CRC)that is known for its diuretic,anti-inflammatory,and swelling-reducing properties.Although its efficacy has been demonstrated in a clinical setting,the active compounds and their mechanisms of action in CRC treatment remain to be fully elucidated.AIM To identify the active,CRC-targeting components of HC and to elucidate the mechanisms of action involved.METHODS Active HC components were identified and screened using databases.Targets for each component were predicted.CRC-related targets were obtained from human gene databases.Interaction targets between HC and CRC were identified.A“drug-ingredient-target”network was created to identify the core components and targets involved.Gene Ontology(GO)and Kyoto Encyclopedia of Genes and Genomes(KEGG)analyses were conducted to elucidate the key pathways involved.Molecular docking between core targets and key components was executed.In vitro experiments validated core monomers.RESULTS Nineteen active components of HC were identified,with acacetin as the primary active compound.The predictive analysis identified 454 targets of the active compounds in HC.Intersection mapping with 2685 CRC-related targets yielded 171 intervention targets,including 30 core targets.GO and KEGG analyses indicated that HC may influence the phosphoinositide 3-kinase(PI3K)/Akt signaling pathway.Molecular docking showed that acacetin exhibited an optimal interaction with AKT1,identifying PI3K,AKT,and P53 as key genes likely targeted by HC during CRC treatment.Acacetin inhibited HT-29 cell proliferation and migration,as well as promoted apoptosis,in vitro.Western blotting analysis revealed increased p53 and cleaved caspase-3 expression and decreased levels of p-PI3K,p-Akt,and survivin,which likely contributed to CRC apoptosis.CONCLUSION Acacetin,the principal active compound in the HC pair,inhibited the proliferation and migration of HT-29 cells and promoted apoptosis through the PI3K/Akt/p53 signaling pathway.
